NYSEAMERICAN:ZOM Zomedica (ZOM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Zomedica Stock (NYSEAMERICAN:ZOM) Get Zomedica alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume790,936 shsAverage Volume4.72 million shsMarket Capitalization$95.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Zomedica Corp. is a veterinary health company that develops and commercializes products for companion animals, with a focus on improving diagnostic testing, treatment, and patient monitoring in veterinary practices. The company primarily serves veterinarians and animal-health professionals in the small-animal and equine markets. Its product portfolio includes the TRUFORMA veterinary diagnostic platform, which is designed to provide point-of-care testing for certain conditions, as well as therapeutic technologies such as PulseVet shock-wave therapy systems. Zomedica has also offered animal-health and wellness products through acquired businesses, including Assisi Animal Health’s noninvasive therapeutic devices and VetGuardian’s remote monitoring technology. Zomedica was established in 2015 and is headquartered in Ann Arbor, Michigan. The company has expanded its offerings through acquisitions and strategic product development, and its operations are oriented toward veterinary practices and animal-health markets in North America and other markets where its products are distributed. Larry Heaton serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Receive ZOM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zomedica and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZOM Stock News HeadlinesZomedica Corp. (ZOMDF) Discusses Clinical Program and Evidence-Driven Adoption in Veterinary Products TranscriptOctober 24, 2026 | seekingalpha.comZomedica Corp. (ZOMDF) Inside Marketing: How Demand Creation Drives Revenue and Supports Distinct Product Portfolios TranscriptSeptember 26, 2026 | seekingalpha.comDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long. Tradewins plans to move the resource behind a paywall soon, closing off free access to the strategy breakdown. Readers who want a copy should grab it now, before the download link expires.October 30 at 1:00 AM | TradeWins (Ad)Zomedica stringe un accordo con un gruppo veterinario per i suoi prodottiSeptember 23, 2026 | it.investing.comZomedica Corp. (ZOMDF) Q2 2026 Earnings Call TranscriptAugust 28, 2026 | seekingalpha.comZomedica Corp.: Zomedica Announces Strategic Collaboration with Boehringer Ingelheim Animal Health Canada Inc. to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA PlatformAugust 13, 2026 | finanznachrichten.deZOMEDICA CORPJuly 30, 2026 | finanznachrichten.deZomedica Corp. (ZOMDF) Discusses Sales Strategy and Execution in Veterinary Medicine TranscriptJuly 25, 2026 | seekingalpha.comSee More Headlines ZOM Stock Analysis - Frequently Asked Questions How were Zomedica's earnings last quarter? Zomedica Corp. (NYSEAMERICAN:ZOM) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($0.01) earnings per share for the quarter. The firm earned $7 million during the quarter. Zomedica had a negative net margin of 232.88% and a negative trailing twelve-month return on equity of 12.47%. Read the conference call transcript. What other stocks do shareholders of Zomedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zomedica investors own include NIO (NIO), SNDL (SNDL), Bionano Genomics (BNGO), Palantir Technologies (PLTR), Tesla (TSLA), Plug Power (PLUG) and Ocugen (OCGN). Company Calendar Last Earnings11/07/2024Today10/30/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSEAMERICAN:ZOM CIK1684144 Webwww.zomedica.com Phone734-369-2555FaxN/AEmployees50Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.53 million Net Margins-232.88% Pretax Margin-232.24% Return on Equity-12.47% Return on Assets-11.84% Debt Debt-to-Equity RatioN/A Current Ratio10.82 Quick Ratio10.15 Sales & Book Value Annual Sales$25.19 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / BookN/AMiscellaneous Outstanding Shares979,950,000Free Float938,890,000Market Cap$95.35 million OptionableNot Optionable Beta1.03 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NYSEAMERICAN:ZOM) was last updated on 3/4/2025 by MarketBeat.com Staff. From Our PartnersA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | SponsoredWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredTrump’s $16 Trillion Chess Move (signed and highlighted)A newly signed executive order could point to one of the largest resource deals in history, according to Matt ...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zomedica Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zomedica With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
